Jennison Associates LLC purchased a new position in shares of Sight Sciences Inc (NASDAQ:SGHT) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 38,733 shares of the company’s stock, valued at approximately $879,000. Jennison Associates LLC owned approximately 0.08% of Sight Sciences as of its most recent SEC filing.
Separately, Deutsche Bank AG bought a new stake in Sight Sciences during the 3rd quarter worth about $162,000. Hedge funds and other institutional investors own 49.01% of the company’s stock.
Shares of SGHT opened at $15.88 on Friday. Sight Sciences Inc has a 52 week low of $15.16 and a 52 week high of $42.57. The firm has a 50-day moving average of $19.43. The company has a current ratio of 27.91, a quick ratio of 27.62 and a debt-to-equity ratio of 0.13.
Several brokerages have commented on SGHT. Zacks Investment Research raised shares of Sight Sciences from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Wednesday. Morgan Stanley raised shares of Sight Sciences from an “equal weight” rating to an “overweight” rating and cut their price target for the stock from $36.00 to $27.00 in a research report on Friday, January 7th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $36.00.
In related news, Director Staffan Encrantz purchased 527,048 shares of the firm’s stock in a transaction that occurred on Monday, October 18th. The shares were acquired at an average price of $24.00 per share, for a total transaction of $12,649,152.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Jesse Selnick acquired 10,000 shares of the business’s stock in a transaction on Tuesday, November 23rd. The stock was acquired at an average cost of $18.44 per share, with a total value of $184,400.00. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 838,108 shares of company stock worth $19,270,384.
About Sight Sciences
Sight Sciences Inc is a medical device company. It focused on the development and commercialization of proprietary devises which target the underlying causes of prevalent eye diseases. Sight Sciences Inc is based in MENLO PARK, Calif.
Read More: Euro STOXX 50 Index
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.